In a significant financial milestone, Xlife Sciences AG invests CHF23.3m in 4D Lifetec AG. With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an AI software developed specifically for 4D Lifetec, which will massively expand the functionality of the 4D Lifetest in the field of digital health. The strategic investment marks a significant turning point in the healthcare industry as it combines financial strength with cutting-edge technology to revolutionize early cancer detection.
4D Lifetec, a pioneer in early cancer detection, owns an immuno-oncology biomarker that has proven its high sensitivity already in cancer stages I and II in numerous clinical studies. The easy-to-use IVD certified blood test enables a unique high-throughput analysis of patient samples, providing a powerful data set that now becomes accessible to train AI through the transaction. Backed up with a substantial investment, 4D Lifetec gains a doorway to innovative AI that will redefine the landscape of cancer diagnosis and access to the digital health network of Xlife Sciences. In addition, the deal also provides the financial strength necessary for implementation.
Zurich-based Xlife Sciences is a publicly traded accelerator and investor company dedicated to addressing unmet medical needs and improving the quality of life through innovative healthcare solutions. Xlife Sciences was among the first to recognize the importance of artificial intelligence in enhancing patient care and outcomes and has built relevant capabilities within its portfolio companies. For early cancer diagnostics, AI resources were pooled in x-diagnostics, which can now unleash its full potential in a clinical context through the transaction. By becoming a new major shareholder in 4D Lifetec, Xlife Sciences adds a leading early cancer diagnostics pioneer to its portfolio network.
Bringing these two technologies together will enable 4D Lifetec to seamlessly integrate data from diverse sources, including patient history, genetic information, and imaging, providing comprehensive decision support for oncologists Dr. Arne-Christian Faisst, Co-founder and Chairman of 4D Lifetec says. This will result definitively in more accurate early cancer diagnoses, ultimately enhancing patient care and outcomes.
Study links TCM with effects on protein networks
Latest NewsBy mapping out associations between human protein networks and herbs used in traditional Chinese medicine (TCM), a Chinese-Bulgarian team can predict relief on various disease symptoms.
Challenges in the central lab
BackgroundClinical trials have to be coordinated as a safe process where monitoring, analytics and handling of patient samples is streamlined – even cross oceans. German MLM Medical Labs is quickly establishing itself as an emerging central and specialty lab in the U.S.
BioNtech reports Car-T/mRNA booster study results at ESMO
Latest NewsBioNtech SE has reported preliminary Phase I/II results with BNT211-01 (NEO-PTC-01) and CarVAC at ESMO conference in Madrid
Roche acquires Telavant Holdings to win TLA1 race
Latest NewsAnalysts describe as sporting the €7.1bn for Roche AG’s acquisition of Roivant subsidiary Telavant Holdings.
UK boosts AMR defenses with £30m PACE initiative
Latest NewsIn an effort to address the global health threat of antimicrobial resistance (AMR), Innovate UK, LifeArc, and Medicines Discovery Catapult have jointly launched the PACE (Pathways to Antimicrobial Clinical Efficacy) initiative. With £30m (around €34,5m) in funding, PACE aims to support early-stage innovations aimed at countering AMR.
CPHI: Trends shaping pharma’s path
Latest NewsThis week CPHI 2023 will unite industry leaders, innovators, and start-ups to explore sustainable solutions, cutting-edge technologies, and collaborative partnerships.
Efficacy evaluation
ProductsAntibody drugs including monoclonal antibodies (mAb), bispecific antibodies, antibody-drug conjugates (ADCs), and nanobodies have sparked a new surge in research and development.
Xlife Sciences AG acquires 20% stake in 4D Lifetec AG
Latest NewsIn a significant financial milestone, Xlife Sciences AG invests CHF23.3m in 4D Lifetec AG. With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an AI software developed specifically for 4D Lifetec, which will massively expand the functionality of the 4D Lifetest in the field of digital health. The strategic investment marks a significant turning point in the healthcare industry as it combines financial strength with cutting-edge technology to revolutionize early cancer detection.
4D Lifetec, a pioneer in early cancer detection, owns an immuno-oncology biomarker that has proven its high sensitivity already in cancer stages I and II in numerous clinical studies. The easy-to-use IVD certified blood test enables a unique high-throughput analysis of patient samples, providing a powerful data set that now becomes accessible to train AI through the transaction. Backed up with a substantial investment, 4D Lifetec gains a doorway to innovative AI that will redefine the landscape of cancer diagnosis and access to the digital health network of Xlife Sciences. In addition, the deal also provides the financial strength necessary for implementation.
Zurich-based Xlife Sciences is a publicly traded accelerator and investor company dedicated to addressing unmet medical needs and improving the quality of life through innovative healthcare solutions. Xlife Sciences was among the first to recognize the importance of artificial intelligence in enhancing patient care and outcomes and has built relevant capabilities within its portfolio companies. For early cancer diagnostics, AI resources were pooled in x-diagnostics, which can now unleash its full potential in a clinical context through the transaction. By becoming a new major shareholder in 4D Lifetec, Xlife Sciences adds a leading early cancer diagnostics pioneer to its portfolio network.
Bringing these two technologies together will enable 4D Lifetec to seamlessly integrate data from diverse sources, including patient history, genetic information, and imaging, providing comprehensive decision support for oncologists Dr. Arne-Christian Faisst, Co-founder and Chairman of 4D Lifetec says. This will result definitively in more accurate early cancer diagnoses, ultimately enhancing patient care and outcomes.
Manufacturing Biopharmaceuticals
BackgroundWithin the competitive CDMO market, Richter-Helm has developed into a highly valued partner when it comes to the manufacturing of biopharmaceuticals. Richter-Helm is well recognised by pharmaceutical companies, including Big Pharma, as a professional partner offering flexible CDMO solutions from gene to product, all from one source, including consultancy services. This makes Richter-Helm one of the key players in CDMO business.
Ikxinta – at the forefront of thriving biotech innovation
Sponsored PublicationsIkxinta, a life sciences advisory firm that originated in the Basque Country in 2018, collaborates with scientists, industry innovators, and investors to propel clients in scientific frontiers